19.07.2019 10:45
Swiss companies including ObsEVa, Molecular Partners and GlycoVaxyn received investment from Medicxi, Europe’s leading life sciences investment firm. Today, Medicxi has closed a new €400 million Fund (Medicxi III), making it one of the largest biotech funds in Europe, to invest in early and late-stage biopharma companies from discovery to late-stage clinical assets.